CONNECTIVE TISSUE DISEASES

Inherited /acquired disorders of connective tissue system

Collagen diseases- unacceptable term

Lupus Erythematosus

Classification

DLE - Localized

- Disseminated

SCLE

SLE Genetically distinct

Somatic mutation

Discoid Lupus Erythematosus

Autoimmune in 50%

Peak age of onset - 40 years

Relatively benign

Mainly affecting face

Characteristic histopathological,

Hematological & Serological changes

ETIOPATHOGENESIS

Genetic factors

3 genotypes according to age of onset HLA B7,B8,CW7,DR2,DR4,DQW1 Somatic mutations at autosomal loci in lymphoid stem cell

- Forbidden clone of lymphocytes synthesizing cellular autoAB's

Environmental factors

Trauma, mental stress, sunburn,
Infection, exposure to cold,
Pregnancy,

Drugs - isoniazid, penicillin, griseofulvin, dapsone

HISTOPATHOLOGY

- Liquefactive degeneration of basal cell layer
- Degenerative changes in connective tissue,
- Hyalinization, oedema, fibrinoid change
- Patchy dermal lymphocyte infiltrate mainly peri-appendageal

Immuno-histology

IgG, IgA, IgM & complement present at DEJ in 80% patients in skin lesions present for more than 6 weeks

Patterns

Homogenous, granular, thready Unlike SLE

- not in uninvolved skin

Clinical Features

Rash over face, cheeks, nose

Other sites

Scalp, ears, arms legs & trunk

Variably sized, well defined erythematous, patches/plaques



Adherent scale - removed horny plugs in dilated pilosebaceous canals — 'Tin-tack'/'carpet tack' sign


Wide follicular pits in ear Heals with atrophy & scarring



Annular atrophic plaques Face, neck, behind ears Warty lesions Nose, ear, temple, scalp **Hyperkeratotic** Arms & legs **Tumid type** Cheek, whole limb LE telangiectoides Face, neck, ears breast, hands








Mucus Membranes

Lips-thick, rough, red,
Superficial ulceration
& crusting



Eye lesions

Oedema & conjunctival redness

Eyelids

Infiltrated, scaly, peripheral redness

Nails

Sub ungual hyperkeratosis,

Red-blue colors of nail plate

Lab Abnormalities

↑ S.globulin - most common(55% patients)

Anemia, leucopenia, thrombocytopenia,

†ESR

False +ve reactions for syphilis

Anti nuclear Ab's - 35%

Differential Diagnosis

Lichen planus

PMLE

Seborrheic dermatitis

Lichen sclerosus

Morphea

Chilblains

Sarcoidosis

Prognosis

Untreated - persistant

Complete remission in 50%

Scarring (57%)

Scarring alopecia (35%)

Long duration -

Raynaud's

Scalp involvement

Chilblains like lesions

Risk of SLE - 6.5% in localised DLE 22% in Disseminated

Treatment

General measures

- Photoprotection

Topical Steroids

Resistant cases - I/L steroids (lips, mouth, ears)

I/L Interferons

CO2 laser

Pulsed dye laser

Argon laser (telangiectatic type)

Oral therapy

Antimalarials

Chloroquine sulphate 200mg B.D Reassessed at 6 weeks

Side effects

Corneal deposits, retinopathy, pigmentation of nails & legs, bleaching of hair, Exfoliative dermatitis, Myopathy, neuropathy, mental disturbances

HCQS(Hydroxychloroquine)

400-800mg B.D

75% patients respond

Oral steroids- if antimalarials fail

Prednisolone 5-15mg/day help in joint

pains & scalp involvement

Others

B-carotene 50mg TDS

Clofazamine 100mg/day

Dapsone 100mg/day

Etretinate 1mg/kg/day

Methotrexate

Thalidomide(100-200/day)

Cyclophosphamide (50-200mg/day)

Gold salts(6-9mg/day)

Phenytoin 100mg TDS

Subacute cutaneous lupus Erythematosus

10% LE patients

Non scarring papulosquamous (2/3)

Annular polycyclic lesions (1/3)

Resolve with grey-white hypopigmentation & telangiectases

- Follicular plugging & hyperkeratosis not prominent
- -Non scarring alopecia & photosensitivity(50%)
- -50% fulfill ARA criteria for SLE (arthritis MC)
- -Fever, malaise & CNS involvement frequent

Mild renal disease Lesional subepidermal Ig deposition(60%) speckled IgG Drugs Hydrochlorthiazide Griseofulvin **PUVA**

Subacute Cutaneous Lupus Erythematosus







Treatment

Sunscreens

Topical steroids

Antimalarials

Oral steroids

Etretinate, Dapsone

Cyclosporine, oral gold

Systemic lupus Erythematosus

- -Systemic association of immunological abnormality with pathological changes in various organs
- -Particularly Skin, joints & vasculature
- F:M 8:1
 - -Age of onset 38 years

Etiopathogenesis

Unknown

Genetic factors

HLA - B8, DR3, A1, DR2, DQ

Auto antibodies

Non organ specific humoral auto AB's

- hallmark

Anti us DNA & Anti Sm Ab's

- More specific

Antinuclear & Anti Sm Ab's

- More common

Environmental factors

- Silicone implants, heavy metals, mercury, gold, & trichloroethylan
- Imee, ms, stress, hormonal factors
- UV radiation
- -Virus Myxovirus
- Drugs –n Hydralazine, minocycline anticonvulsant, procainamide

Histopathology

Hyperkeratosis without parakeratosis
liquifactive degeneration of basal cell
Edema in dermis with vesicle formation
at DEJ

Perivascular lymphocyte infiltration

Immuno Histology

Predominantly IgG, IgM, IgA with complement

C1,C3 at DEJ in 80% patients

Uninvolved skin from exposed area - 75%

Uninvolved unexposed skin +ve in 50%

Immunoflurosence patterns


Homogenous

Old lesions

strippled

Uninvolved skin New lesions

thready





Characteristic microscopic features

Haematoxylin bodies in heart valves

Periarterial fibrosis

Wire-loop lesions in kidney

Clinical Features

Arthritis

Cutaneous changes

Renal abnormality

Psychiatric disturbance


Serological findings

Pericarditis

Pleurisy

Abdomen pain

PUO, Menstrual disturbances, Raynaud's



American Rheumatism Association Criteria for SLE 1.Malar Rash






2. Discoid rash




3. Photosensitivity





4. Oral ulcers - Palate



5. Non erosive arthritis




- 6. Serositis-Pleurisy/ pericarditis
- 7. Kenal disorder (Persistent proteinuria >0.5g/d or cellular casta)
- 8. Neurologia Luzures/ psychosis
- 9. Hematological Hemolytic anemia, leucopenia, thrombocytopenia
- 10. Immunological LE cells, anti DNA Ab, anti Sm Ab
- 11. Antinuclear Ab's

Lab Investigations

LE cell Test (80%)

LE cells are polymorph with ingested nuclear material from degen. WBC's (those of an Ab to deoxyribonucleoprotein)



Treatment

Optimal function with minimal disease

General - Photoprotection

Steroids - Prednisolone 60mg/day,

↓ 10- 15mg/d

Chloroquine/HCQS - Less useful

Immuno suppressives - Azathiophine,

Cyclophosphamide

Plasmapheresis, Cyclosporin, Methotrexate